Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented different innovative pricing and reimbursement models. In an article for MedTech Strategist, we explore whether similar innovative reimbursement and contracting schemes might be developed for medical technologies and how the challenges they bring might be overcome.
Prioritising Alzheimer’s disease policy in Europe: Insights from oncology
However, current levels of policy development do not reflect the urgency for change, especially given the progress made in understanding the disease and new...